NovoCure Ltd. (NASDAQ:NVCR) shares shot up 3.4% during trading on Thursday . The stock traded as high as $8.14 and last traded at $8.02, with a volume of 158,955 shares traded. The stock had previously closed at $7.76.

A number of analysts have recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price target on shares of NovoCure in a research note on Tuesday, May 10th. Zacks Investment Research lowered shares of NovoCure from a “hold” rating to a “sell” rating in a research note on Friday, May 13th. Barclays PLC reduced their price target on shares of NovoCure from $12.00 to $9.00 and set an “underweight” rating for the company in a research note on Friday, July 29th. Deutsche Bank AG reduced their price target on shares of NovoCure from $28.00 to $16.00 and set a “hold” rating for the company in a research note on Friday, July 29th. Finally, JMP Securities reduced their price target on shares of NovoCure from $43.00 to $34.00 and set a “market outperform” rating for the company in a research note on Friday, July 29th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. NovoCure presently has an average rating of “Hold” and an average target price of $21.43.

The firm’s market capitalization is $687.91 million. The company’s 50 day moving average is $9.98 and its 200-day moving average is $11.99.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings data on Thursday, July 28th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.11. The firm had revenue of $17.90 million for the quarter, compared to the consensus estimate of $15.90 million. On average, equities research analysts predict that NovoCure Ltd. will post ($1.95) EPS for the current year.

In related news, COO Michael J. Ambrogi sold 20,000 shares of the stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $12.24, for a total transaction of $244,800.00. Following the completion of the sale, the chief operating officer now owns 324,084 shares in the company, valued at approximately $3,966,788.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gert L. Perlhagen sold 676,576 shares of the stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $1.85, for a total transaction of $1,251,665.60. Following the sale, the director now owns 676,576 shares of the company’s stock, valued at approximately $1,251,665.60. The disclosure for this sale can be found here.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.